A recently cleared phase 3 study (NCT06051409) will evaluate olverembatinib combined with chemotherapy as a first-line ...

Based on the primary PFS analysis of EMBER-3, the FDA approved single-agent imlunestrant in September 2025 for the treatment of patients with ER+/HER2– ESR1 m advanced breast cancer with disease ...

The FDA approved niraparib and abiraterone acetate plus prednisone for BRCA2-mutated mCSPC, based on the AMPLITUDE trial's rPFS results. FDA approves a new treatment combining niraparib and ...

Hormone replacement therapy (HRT) does not increase breast cancer risk in BRCA1/BRCA2 carriers, with estrogen-alone formulations showing a lower risk. The study used a matched-pair design to control ...

Infection management in hematologic malignancies is critical due to higher mortality risks, necessitating improved communication between patients and providers. Remote therapeutic monitoring platforms ...

Long-term follow-up in the PALLAS study showed no overall survival benefit with palbociclib plus endocrine therapy compared to endocrine therapy alone in hormone receptor-positive, HER2-negative ...

Elacestrant combined with everolimus or abemaciclib showed significant PFS benefits in ER-positive, HER2-negative metastatic breast cancer patients. The ELEVATE trial reported median PFS of 8.3 months ...

A tumor-informed ctDNA assay identified MRD in TNBC patients, indicating a 30-fold higher risk of distant recurrence for MRD-positive individuals. The NSABP B-59/GBG 96-GeparDouze trial involved 1550 ...

Sacituzumab govitecan and pembrolizumab showed a manageable safety profile in PD-L1–positive metastatic TNBC, with lower dose reduction or discontinuation rates than chemotherapy. The combination ...

Early results from the OLYMPIA-3 trial reveal odronextamab plus CHOP chemotherapy shows promising efficacy for untreated ...

Explore the advantages and challenges of long-term red blood cell transfusions for low-risk MDS patients, focusing on quality ...

Long-term follow-up of the IMEG trial reveals potential survival benefits of a metal stent in low-risk MDS patients, ...